Lexaria Provides Partial 8-Week Interim Results Update On Phase 1b, 12-Week Chronic Study GLP-1-H24-4, Currently Underway In Australia, Focusing On DHT GLP-1 Study Arms 2 And 5 Relative To Rybelsus Control Study Arm 4

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®

DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®

DehydraTECH-GLP-1 study arms evidencing patient safety and tolerability consistent with the primary study endpoint

KELOWNA, BC / ACCESS Newswire / July 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following partial 8-week positive interim results update on the phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), currently underway in Australia, focusing on the DehydraTECH ("DHT") glucagon-like peptide-1 ("GLP-1") study arms 2 and 5 relative to the Rybelsus® control study arm 4.

Lexaria's average DHT-semaglutide weight loss results after 8 weeks are tracking similar to the historical performance of Rybelsus® in the much larger Pioneer studies, which is thus far encouraging to see.

Curiously, the Rybelsus® body weight performance data in the current Lexaria Study appears to be much stronger than the results shown above in both the 26-week Pioneer 1 study and in the Pioneer 6, 8-week interim data. The reasons for this apparent anomaly are presently unknown, but likely related to the small sample size of the Lexaria Study. The historical studies conducted in thousands of persons are more likely to be representative of real-world performance.

For HbA1c levels it is important to understand that HbA1c measures blood glucose over a 8-12 week period of time, thus the current 8-week data from Lexaria's Study is barely relevant compared to expected 12-week data. Furthermore, there is no statistically significant difference between the DHT-semaglutide and Rybelsus® reductions in HbA1c witnessed at the 8-week point thus far in the Study (p=0.069). The 12-week HbA1c data should be more representative, and potentially, quite different from the 8-week data.

Additional 8-week interim Study data may or may not be released as it is more fully processed and understood in the weeks to come. The vast majority of laboratory-derived data, including a battery of additional safety, tolerability and efficacy parameter assessments beyond those summarized here, and all final results will not be available until near the end of calendar-2025. The Study is currently approaching the "last patient last visit" milestone and remains on schedule.